Nalfon (fenoprofen calcium) is a nonsteroidal, anti-inflammatory, antiarthritic drug that also possesses analgesic and antipyretic activities. Its exact mode of action is unknown, but it is thought that prostaglandin synthetase inhibition is involved.
Results in humans demonstrate that fenoprofen has both anti-inflammatory and analgesic actions. The emergence and degree of erythemic response were measured in adult male volunteers exposed to ultraviolet irradiation. The effects of Nalfon (fenoprofen calcium) , aspirin, and indomethacin were each compared with those of a placebo. All 3 drugs demonstrated antierythemic activity.
In all patients with rheumatoid arthritis, the anti-inflammatory action of Nalfon (fenoprofen calcium) has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). The anti-inflammatory action of Nalfon (fenoprofen calcium) has also been evidenced by increased mobility (i.e., a decrease in the number of joints having limited motion).
The use of Nalfon (fenoprofen calcium) in combination with gold salts or corticosteroids has been studied in patients with rheumatoid arthritis. The studies, however, were inadequate in demonstrating whether further improvement is obtained by adding Nalfon (fenoprofen calcium) to maintenance therapy with gold salts or steroids. Whether or not Nalfon (fenoprofen calcium) used in conjunction with partially effective doses of a corticosteroid has a "steroid-sparing" effect is unknown.
In patients with osteoarthritis, the anti-inflammatory and analgesic effects of Nalfon (fenoprofen calcium) have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints.
In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown Nalfon (fenoprofen calcium) to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with Nalfon (fenoprofen calcium) than in aspirin-treated patients. It is not known whether Nalfon (fenoprofen calcium) causes less peptic ulceration than does aspirin.
In patients with pain, the analgesic action of Nalfon (fenoprofen calcium) has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect.
Under fasting conditions, Nalfon (fenoprofen calcium) is rapidly absorbed, and peak plasma levels of 50 ug/mL are achieved within 2 hours after oral administration of 600 mg doses. Good dose proportionality was observed between 200 mg and 600 mg doses in fasting male volunteers. The plasma half-life is approximately 3 hours. About 90% of a single oral dose is eliminated within 24 hours as fenoprofen glucuronide and 4'-hydroxyfenoprofen glucuronide, the major urinary metabolites of fenoprofen. Fenoprofen is highly bound (99%) to albumin.
The concomitant administration of antacid (containing both aluminum and magnesium hydroxide) does not interfere with absorption of Nalfon (fenoprofen calcium) .
There is less suppression of collagen-induced platelet aggregation with single doses of Nalfon (fenoprofen calcium) than there is with aspirin.
Last reviewed on RxList: 8/4/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Nalfon Information
Nalfon - User Reviews
Nalfon User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options